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To determine whether heart failure with preserved systolic function (HFPSF) has different 
natural history from left ventricular systolic dysfunction (LVSD). 
 
Design and setting:  
A retrospective analysis of 10 years of data (for patients admitted between 1 July 1994 and 30 
June 2004, and with a study census date of 30 June 2005) routinely collected as part of 
clinical practice in a large tertiary referral hospital. 
 
Main outcome measures:  
Sociodemographic characteristics, diagnostic features, comorbid conditions, 
pharmacotherapies, readmission rates and survival. 
 
Results:  
Of the 2961 patients admitted with chronic heart failure, 753 had echocardiograms available 
for this analysis. Of these, 189 (25%) had normal left ventricular size and systolic function. In 
comparison to patients with LVSD, those with HFPSF were more often female (62.4% v 
38.5%; P = 0.001), had less social support, and were more likely to live in nursing homes 
(17.9% v 7.6%; P < 0.001), and had a greater prevalence of renal impairment (86.7% v 6.2%; 
P = 0.004), anaemia (34.3% v 6.3%; P = 0.013) and atrial fibrillation (51.3% v 47.1%; P = 
0.008), but significantly less ischaemic heart disease (53.4% v 81.2%; P = 0.001). Patients 
with HFPSF were less likely to be prescribed an angiotensin-converting enzyme inhibitor 
(61.9% v 72.5%; P = 0.008); carvedilol was used more frequently in LVSD (1.5% v 8.8%; P 
< 0.001). Readmission rates were higher in the HFPSF group (median, 2 v 1.5 admissions; P 
= 0.032), particularly for malignancy (4.2% v 1.8%; P < 0.001) and anaemia (3.9% v 2.3%; P 
< 0.001). Both groups had the same poor survival rate (P = 0.912). 
 
Conclusions:  
Patients with HFPSF were predominantly older women with less social support and higher 
readmission rates for associated comorbid illnesses. We therefore propose that reduced 









It is conservatively estimated that between a third and half of patients hospitalised for 
decompensated heart failure have heart failure with preserved systolic function (HFPSF).1 
Despite the prevalence of this syndrome, there are no robust, generally agreed diagnostic 
criteria for diastolic heart failure. International definitions of HFPSF2-4 define patients as 
having symptoms (shortness of breath, fatigue, orthopnea) or clinical signs of fluid retention 
(pulmonary, abdominal, or peripheral), and normal to near-normal systolic function on 
echocardiography (left ventricular ejection fraction [LVEF] > 45%),2 with clinical 
improvement in response to conventional treatment for chronic heart failure (CHF), if the 
diagnosis is in doubt. 
 
Patients with HFPSF have a distinct demographic profile, aetiological background and 
pathophysiology.1,5 Compared with patients who have a low ejection fraction, previous 
studies suggest that those with HFPSF are generally older, are more often women, and are 
more likely to have CHF of hypertensive aetiology.6,7 
HFPSF also has a different natural history compared with heart failure with left ventricular 
systolic dysfunction (LVSD), despite producing a similar symptom burden and mortality.1,8 
The multiple comorbid conditions frequently associated with HFPSF contribute substantially 
to the risk of hospitalisation as HFPSF progresses.8,9 
To date, most of the data on the epidemiology and natural history of HFPSF, and the 
associated disease burden, have come from clinical trials.7 Treatment for HFPSF remains 
largely empirical, as most drugs and devices that have been shown to reduce morbidity and 
mortality in heart failure have predominantly been tested in patients with LVSD.7 
Accordingly, we undertook to characterise the demographics, pharmacotherapy, readmission 




We performed a retrospective analysis of longitudinal clinical data collected during routine 
management from a cohort of 2961 patients admitted to a large tertiary referral hospital with 
a diagnosis of CHF. Patients with CHF who were admitted to the general medical or 
cardiology units between 1 July 1994 and 30 June 2004 were included. Follow-up was 
performed from index admission to either death or study census (30 June 2005). The data 
included were for all index and subsequent admissions for eligible patients. 
Admissions data and patient demographic information were acquired from hospital electronic 
records, with death data obtained from the National Death Index (developed and maintained 
by the Australian Institute of Health and Welfare). Comorbid conditions were derived from 
International Classification of Diseases, 10th revision (ICD-10) coding, and the medications 
prescribed from pharmacy dispensing data. Results of biochemical analyses were extracted 
using linked records from the hospital pathology service. 
 
Diagnosis and other study definitions 
For the purpose of this study, CHF was defined according to recently published international 
guidelines.6-8 About 1000 casenotes for the cohort were reviewed and scored for the 
diagnosis of CHF using the Framingham criteria.10 This confirmed the specificity of ICD 
codes for principal diagnosis of CHF as being greater than 99%. Hence, the ICD codes for 
CHF were accepted for the remainder of the cohort. 
Echocardiography data were derived from the hospital’s echocardiogram database. Standard 
biplane LVEF was calculated by means of Simpson’s method of disc,11 following manual 
tracing of endocardial borders. Preserved systolic function was defined as an LVEF over 
45%2 or, in the absence of a quantitative assessment, a subjective report of normal left 
ventricular size and systolic function. 
 
We used the following definitions for hospitalisations: 
• Length of stay — the number of days the patient occupied a bed, inclusive of 
admission and discharge dates. 
• CHF-related hospitalisations — identified by a discharge diagnosis coding of CHF in 
either the first or second diagnostic position for an unplanned hospitalisation.12 
• All-cause hospitalisations — all unplanned admissions to hospital for any cause. 
Comparative baseline mortality and population data were obtained from the South Australian 
Department of Health. 
 
Statistical analysis 
Data analysis was performed with SPSS, version 17.0 (SPSS Inc, Chicago, Ill, USA). Cohort 
characteristics were compared using the Mann–Whitney U test for non-parametric data, and 
associations between groups determined by Pearson’s χ2 test for categorical data. As the data 
analysed covered an 11-year overall study period, during which time there were fatal events, 
the number of patients at risk of an event (hospitalisation or death) for each month of the year 
and for each year of follow-up was calculated according to index admission dates and dates 
of death until the census date (30 June 2005), allowing adjustment for study entry and death. 
Survival data were compared using Kaplan–Meier analysis and Cox proportional hazards 
regression modelling. 
Length of stay for CHF-related admissions was analysed by adding the numbers of bed-days 
accumulated for each month over the 11-year study period and dividing this by the total 
number of CHF-related admissions accumulated per month over the same period. 
 
Ethics approval 
All patient data were de-identified before analysis. Ethics approval was obtained from the 
Royal Adelaide Hospital Research Ethics Committee. Our study conformed to the principles 
outlined in the Declaration of Helsinki.13 
 
Results 
Of the 2961 patients admitted with CHF during the 10-year admission period of this study, 
there were 753 with echocardiograms available for analysis. Of these, 189 (25%) showed 
normal left ventricular size and systolic function; these patients comprised the HFPSF cohort, 
while the remaining 564 were the LVSD cohort. 
 
Box 1 shows that the mean age of patients in the HFPSF cohort was 2 years older than that of 
patients in the LVSD cohort. 
 
Patients with HFPSF were much more likely to be women, and were more likely to have 
fewer social supports, less likely to be married and more likely to be widowed, less likely to 
live in their own home and more likely to be living in a nursing home (Box 1). 
 
Comorbid conditions 
Patients with HFPSF were more likely to have other associated comorbid conditions such as 
renal impairment (86.7% v 6.2%; P = 0.004), anaemia (34.3% v 6.3%; P = 0.013) and atrial 
fibrillation (51.3% v 47.1%; P = 0.008), and less likely to have ischaemic heart disease 
(53.4% v 81.2%; P = 0.001) than those with LVSD. 
 
Pharmacotherapy 
Box 2 shows that patients with HFPSF were less likely than those with LVSD to be 
prescribed an angiotensin-converting enzyme inhibitor, carvedilol, or an angiotensin II 
receptor antagonist. Overall, patients with HFPSF were just as likely as those with LVSD to 
be prescribed any other β-blockers, or spironolactone. Despite the greater prevalence of atrial 
fibrillation in the HFPSF cohort, prescription of digoxin did not differ between the two 
cohorts (Box 2). 
 
Morbidity, mortality and readmission 
The mean follow-up period for all 753 patients with CHF was 4.1 years (SD, 0.13 years). 
Despite the HFPSF group having more prognostically significant comorbid conditions, such 
as anaemia and atrial fibrillation, there was no significant difference in patient survival 
between groups (P = 0.912; Box 3). 
 
Box 4 shows that, after controlling for sex and preserved systolic function, multivariate 
predictors of survival included left ventricular size, and the presence of multiple additional 
comorbid conditions (dementia, renal failure, cerebrovascular disease, peripheral vascular 
disease, chronic obstructive pulmonary disease). Younger age (< 75 years; hazard ratio [HR], 
0.033; P < 0.001) and a history of hypertension (HR, 0.004; P = 0.004) were associated with 
improved survival. 
 
There was an increase in the risk of re-hospitalisation among patients with HFPSF, with a 
median of two admissions per year compared with a median of 1.5 admissions per year for 
patients with LVSD (Box 1). 
 
Patients with HFPSF were more likely than those with LVSD to be admitted for diabetes (P < 
0.001), anaemia (P < 0.001) and malignancy (P < 0.001), whereas patients with LVSD were 
more likely to have admissions directly related to heart failure (P < 0.001). There was no 
significant difference in the prevalence of hypertension between the LVSD and the HFPSF 
groups (P = 0.23). Patients with HFPSF had a higher echocardiographic prevalence of left 
ventricular hypertrophy (46.0% v 29.2%; P < 0.001). There were no statistical differences 




We undertook this study to characterise the demographic characteristics, pharmacotherapy, 
readmission rates and survival of patients with HFPSF from clinical data collected for 
patients admitted over a period of 10 years. The demographic characteristics of our HFPSF 
group closely mirrored those reported in other epidemiological studies. In particular, patients 
with HFPSF were more likely to be women and more likely to be older (age, > 75 years).6,7 
Importantly, our study is the first to identify significant differences in the social environment 
of these patients. Specifically, patients with HFPSF were less likely to live in their own 
home, or have a spouse. Lack of social and carer support may have played a significant 
predisposing role in hospitalisation and readmissions.14,15 
 
Patients with HFPSF had a higher prevalence of associated comorbid conditions, such as 
anaemia and atrial fibrillation, and such conditions have the potential to influence 
readmission and survival. Comorbid conditions may also have played a role in the therapeutic 
decision making of clinicians, potentially adversely impacting the intensity of therapy.16 
Other studies have shown that patients with HFPSF were more likely to have hypertensive 
aetiology,7 but we found no significant difference in the prevalence of hypertension between 
the LVSD and the HFPSF groups. The higher echocardiographic prevalence of left 
ventricular hypertrophy among HFPSF patients suggests that this result may be due to 
variability in the coding of hypertension, rather than accurately reflecting the true historical 
prevalence of this condition in each cohort. 
 
We observed that patients with HFPSF received less intensive pharmacological management 
than patients with LVSD. The evidence for pharmacotherapy in HFPSF is less rigorous than 
in LVSD but there are recognised studies supporting the importance of HFPSF 
pharmacotherapies.2-4 Patients with HFPSF were less likely to be prescribed an angiotensin-
converting enzyme inhibitor, despite such agents having been shown to reduce hospitalisation 
rates and improve functional capacity in patients with HFPSF in randomised clinical trials.17 
It is well appreciated that β-blockers have numerous theoretical benefits in patients with 
HFPSF, including lowering of heart rate (potentially improving diastolic filling and coronary 
blood flow, particularly during activity), reduction in myocardial oxygen demand and, by 
lowering the blood pressure, regression of left ventricular hypertrophy.18 Heart rate 
reduction is known to be particularly important in the treatment of pulmonary congestion as a 
result of diastolic heart failure secondary to ischaemia, and in patients with atrial 
fibrillation,19 and has recently been identified as an important determinant of β-blocker 
efficacy in the prevention of early mortality in LVSD. 
 
As with β-blockers, atrial fibrillation may also have contributed to the similar prescription 
rates for digoxin in both patients with HFPSF and LVSD, despite concerns that have been 
raised about the use of digoxin in HFPSF. Classically, digitalis glycosides are known to 
increase intracellular calcium concentrations, potentially impairing myocardial relaxation and 
further worsening diastolic dysfunction. It is possible, however, that the sympatho-inhibitory, 
pro-parasympathetic and renin, angiotensin and aldosterone suppressing actions of digoxin 
are beneficial in HFPSF, but this remains to be proven in the clinical setting.20 
 
We observed a higher rate of hospital readmission in the HFPSF cohort compared with the 
LVSD cohort. Previous reports, however, have identified readmission rates that were 
lower12,21,22 or comparable6,23,24 to those of patients with LVSD. Notably, our HFPSF 
cohort was older, with less social support, and a greater burden of comorbid conditions, so 
readmission cannot be attributed solely to differences in cardiac systolic function. 
 
It has been suggested that HFPSF confers a better prognosis than heart failure with impaired 
systolic function in terms of morbidity and mortality. Studies that examined cohorts 
comparable to those in our study (mean age, > 65 years) have reported similar mortality rates 
among patients with HFPSF and LVSD.6,23,24 On the other hand, previous studies in 
younger populations (mean age, < 65 years) have shown better survival for HFPSF than 
LVSD.6,23,24 Whether such differences relate to differences in the relative malignancy of 
the underlying aetiology among younger LVSD patients, or are the result of an excess burden 
of morbidity and mortality related to comorbid illnesses and social isolation in the older 
HFPSF population remains uncertain. 
 
In older patients, the clinical syndrome of CHF carries a uniformly poor prognosis regardless 
of the level of systolic function. Our findings, and those of similar studies, serve to heighten 
awareness of the prognostic impact of HFPSF, particularly among older patients.7 
Numerous guidelines now indicate that Doppler-based parameters (eg, the ratio of peak early-
diastolic transmitral flow velocity to peak early-diastolic mitral annular velocity [E/E' ratio] 
and pulmonary vein velocities) may be used to further clarify the diagnosis of diastolic 
impairment in the diagnosis of HFPSF. However, our study has shown a significant 
independent survival disadvantage, regardless of these Doppler-based parameters, when 
clinical findings of CHF are associated with normal systolic left ventricular function. It 
remains to be determined whether these Doppler echocardiographic parameters, coupled with 
novel diagnostic biomarkers such as brain natriuretic peptide, provide incremental prognostic 
value in the management of patients with HFPSF in routine clinical practice.25-28 
 
Our study has a number of limitations that require comment. These data are based on a cohort 
of patients from a single tertiary institution. Despite this, the clinical data available for this 
cohort were substantially more detailed than reported previously. The index admission was 
that recorded at the tertiary hospital of interest; however, readmissions data from all tertiary 
and some regional hospitals throughout the state were used to ensure the maximum possible 
readmissions data were captured.7 
 
The clinical underutilisation of echocardiography was a considerable limitation of this study. 
Capturing echocardiography data was complicated by patients having been discharged before 
an echocardiogram was performed, and those who had used private imaging services after 
discharge making records inaccessible. Although there may have been a bias towards patients 
with more severe symptoms having echocardiogram data available, this is unlikely to alter the 
findings of our study with regard to the characteristics of those with impaired compared with 
preserved systolic function. 
 
Prescribing data reflected what patients were dispensed from the hospital pharmacy, but do 
not capture medications on ward stock, such as loop diuretics, and do not take into account 
potential changes to pharmacotherapy after discharge. 
 
In the context of less compelling evidence for aggressive cardiopharmacological 
management, our study shows that these predominantly older female patients with HFPSF 
had less social support and higher readmission rates for associated comorbid illnesses. We 
propose that the burden of reduced survival in HFPSF may relate more to comorbid 
conditions than suboptimal cardiac management. Therefore, we would warn clinicians to 
caveat anicula! — beware of the little old lady with a “normal” echocardiogram. 
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